ReviewInfectious diseases and therapy2024
Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis.
Review in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Burden of Respiratory Syncytial Virus Infection in Immunocompromised Adults: A Systematic Review of the Evidence From High-Income Countries.Infectious diseases and therapy · 2026Pooled it
- The risk of cardiac disease events after respiratory syncytial virus disease: a systematic literature review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- The risk of cardiovascular, cerebrovascular and thromboembolic events after community-acquired pneumonia among adults: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands.Infectious diseases and therapy · 2026Article
- An Appraisal of the Potential Downstream Benefits of RSV Vaccination in Older Adults.Reviews in medical virology · 2026Review
- Clinical and human burden of respiratory syncytial virus in older adults: a narrative review with emphasis on Italian data.Aging clinical and experimental research · 2026Review
- Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.Open forum infectious diseases · 2026Article
- Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- New Tools Against Old Enemies: Respiratory Syncytial Virus (RSV) in Older Adults. A Narrative Review.Farmaceuticos comunitarios · 2026Article
- Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017-2024.Infectious diseases and therapy · 2026Article
- Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus-Related Hospitalization.JAMA network open · 2026Article
- Recovery from COVID-19 may take more than just time.BMJ open respiratory research · 2025Article
- Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults.PLoS medicine · 2025Article
- Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Norway between 2010 and 2019: A Time-Series Modelling Study.Journal of epidemiology and global health · 2025Article
- Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older.Infectious diseases and therapy · 2025Article
- Detection by Nasopharyngeal Swabs Alone Underestimates Respiratory Syncytial Virus-Related Hospitalization Incidence in Adults: The Multispecimen Study's Final Analysis.The Journal of infectious diseases · 2025Article
- Observational
- Saudi Heart Association Position Statement on Adult Vaccinations for Patients With Cardiovascular Diseases.Journal of the Saudi Heart Association · 2025Article
- Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.JAMA network open · 2024Article
- RSV Risk Profile in Hospitalized Adults and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.Infectious diseases and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) can cause severe respiratory infections in adults; however, information on associated sequelae is limited. This systematic literature review aimed to identify sequelae in adults within 1 year following RSV-related hospitalization or resolution of acute infection.
methodsStudies were identified from Embase, MEDLINE, LILACS, SciELO, and grey literature. Random-effects meta-analyses using restricted maximum likelihood were used to calculate the proportions and relative risks of sequelae in patients with RSV compared with controls (patients with RSV-negative influenza-like illness, influenza, and parainfluenza) per follow-up period, population, and treatment setting, where possible.
resultsTwenty-one relevant studies covering the period from 1990 to 2019 were included. Among the general population, the most frequent clinical sequela was sustained function loss (33.5% [95% CI 27.6-39.9]). Decline in lung function and cardiovascular event or congestive heart failure were also identified. Utilization sequelae were readmission (highest at > 6 months after discharge) and placement in a skilled nursing facility. The only subpopulation with data regarding sequelae was transplant patients. Among lung transplant patients, the most frequently reported clinical sequelae were decline in lung function, followed by graft dysfunction and bronchiolitis obliterans syndrome. Pooled relative risks were calculated for the following sequela with controls (primarily influenza-positive patients): cardiovascular event (general population) and pulmonary impairment (hematogenic-transplant patients) both 1.4 (95% CI 1.0-2.0) and for readmission (general population) 1.2 (95% CI 1.1-1.3).
conclusionsAlthough less data are available for RSV than for influenza or other lower respiratory tract infections, RSV infection among adults is associated with medically important sequelae, with a prevalence similar to other respiratory pathogens. RSV sequelae should be included in disease burden estimates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.